]tyrosine were applied to assess in vivo dietary protein digestion and absorption kinetics and subsequent muscle protein synthesis rates during sleep. We found that exogenous phenylalanine appearance rates increased following protein administration. The latter stimulated protein synthesis, resulting in a more positive overnight whole body protein balance (0.30 Ϯ 0.1 vs. 11.8 Ϯ 1.0 mol phenylalanine·kg Ϫ1 ·h Ϫ1 in PLA and PRO, respectively; P Ͻ 0.05). In agreement, overnight muscle protein fractional synthesis rates were much greater in the PRO experiment (0.045 Ϯ 0.002 vs. 0.029 Ϯ 0.002%/h, respectively; P Ͻ 0.05) and showed abundant incorporation of the amino acids ingested via the intrinsically labeled protein (0.058 Ϯ 0.006%/h). This is the first study to show that dietary protein administration during sleep is followed by normal digestion and absorption kinetics, thereby stimulating overnight muscle protein synthesis. Dietary protein administration during sleep stimulates muscle protein synthesis and improves overnight whole body protein balance. These findings may provide a basis for novel interventional strategies to attenuate muscle mass loss.
AGING IS ACCOMPANIED BY A progressive decline in skeletal muscle mass and strength, leading to the loss of functional capacity and an increased risk of developing chronic metabolic disease (19, 25) . Disturbances in skeletal muscle protein turnover result in a structural imbalance between protein synthesis and breakdown, leading to sarcopenia (14) . Because basal (fasting) muscle protein synthesis rates do not seem to differ substantially between the young and elderly (28, 46) , many research groups have started to focus on the muscle protein synthetic response to the main anabolic stimuli, i.e., food intake and physical activity (47) . Recent studies suggest that the skeletal muscle protein synthetic response to food intake is blunted in the elderly (11, 25) . The latter is now believed to represent a key factor responsible for the age-related decline in skeletal muscle mass (25) . Consequently, we as well as other laboratories have been trying to define effective interventional strategies to compensate for the greater anabolic resistance by improving postprandial muscle protein accretion in the elderly. The latter has been applied successfully by increasing the amount of dietary protein ingested (45) , changing the protein source applied (8, 34) , and/or by coingesting additional free leucine (27, 37) . However, besides increasing the postprandial muscle protein synthetic response to a single meal, we questioned whether we could compensate for anabolic resistance in the elderly by stimulating overnight muscle protein synthesis.
Recently, we assessed overnight muscle protein synthesis rates in vivo in males (3) . Because overnight muscle protein synthesis rates were shown to be quite low, we questioned whether limited plasma amino acid availability prevents overnight muscle protein synthesis rates to be elevated above basal levels. Consequently, we questioned whether protein provision during sleep would be followed by proper dietary protein digestion and absorption kinetics, resulting in a substantial increase in plasma amino acid availability. Although data on gut function during sleep are scarce, it has been reported that human intestinal motility follows a circadian rhythm with reduced nocturnal activity (16, 23, 29) . Therefore, we first need to determine whether dietary protein provision during sleep allows the digestive tract to function properly. If so, it should be assessed whether an overnight increase in plasma amino acid availability stimulates mixed-muscle protein synthesis and, as such, improves overnight net protein balance. The latter would greatly increase the window of opportunity to modulate muscle protein metabolism and provides an interesting concept upon which novel interventional strategies can be developed to effectively attenuate muscle mass loss in both health and disease.
Following up the work by Boirie et al. (9) we recently introduced the application of specifically produced intrinsically L-[1- 13 C]phenylalanine-labeled dietary protein as a means to accurately assess in vivo dietary protein digestion and absorption kinetics and subsequent muscle protein synthesis in humans (44) . In the present study, we assess in vivo dietary protein digestion and absorption kinetics and the subsequent muscle protein synthetic response following dietary protein administration via a nasogastric tube during sleep in elderly men. We hypothesized that dietary protein provision during sleep is accompanied by normal protein digestion and absorption kinetics, thereby stimulating muscle protein synthesis and allowing net muscle protein accretion to occur during overnight sleep. This study establishes proof-of-principle of the efficacy of nighttime protein provision to stimulate muscle protein accretion in the elderly. This novel nutritional intervention concept may prove to be of important clinical relevance to attenuate muscle mass loss.
MATERIALS AND METHODS

Subjects.
A total of 16 healthy, normoglycemic, elderly men (74 Ϯ 1 yr) were selected to participate in the present study. Subjects' characteristics are presented in Table 1 . Subjects were randomly assigned to either the placebo (PLA) or protein (PRO) experiment. No differences were observed in subjects' characteristics between experimental groups. All subjects were informed of the nature and possible risks of the experimental procedures before their written informed consent was obtained. This study was approved by the Medical Ethical Committee of the Maastricht University Medical Center, Maastricht, The Netherlands.
Pretesting. All participants performed an oral glucose tolerance test before inclusion in the study. Following an overnight fast, participants arrived at the laboratory at 0800 by car or public transport. Plasma glucose concentrations were measured to determine oral glucose intolerance and/or the presence of type 2 diabetes according to 2006 American Diabetes Association guidelines (10a). Leg volume was measured by anthropometry as described by Jones and Pearson (20) . Directly after the oral glucose tolerance test, body weight, body composition, and bone mineral content were measured with DXA (Lunar Prodigy Advance; GE Health Care, Madison, WI). The system's software package (en-CORE 2005, version 9.15.00) was used to determine whole body and regional lean mass, fat mass, and bone mineral content.
Diet and physical activity in testing. All volunteers were instructed to refrain from any exhaustive physical activity and to keep their diet as constant as possible 3 days before the trial. Food intake and physical activity records were collected for 2 days before the experiment and were analyzed by a certified dietician. Overall (n ϭ 16), habitual daily energy intake was 8.6 Ϯ 0.4 MJ, providing 57 Ϯ 1 energy/100% energy (En%) carbohydrate, 31 Ϯ 1 En% fat, and 12 Ϯ 0.1 En% protein. Total carbohydrate, fat, and protein intake averaged 299 Ϯ 14, 73 Ϯ 3, and 63 Ϯ 3 g, respectively. Dietary protein intake averaged 0.80 Ϯ 0.04 g·kg body wt Ϫ1 ·day Ϫ1 . On the day of the experiment, subjects consumed a standardized breakfast, midmorning snack, lunch, midafternoon snack, and dinner. The standardized diet (3 meals and 2 snacks) provided 9.8 MJ and provided 58 En% carbohydrate, 30 En% fat, and 12 En% protein. Dietary protein intake averaged 0.89 Ϯ 0.09 g/kg body wt, with 30% of the protein provided with dinner. In the morning following the nocturnal intervention, hunger rating was assessed using the visual analog scale (36) . Subsequently, subjects were invited to have breakfast, for which they were provided with a large range of products that could be consumed ad libitum. Food intake at breakfast was recorded for all subjects.
Study design. An outline of the study protocol is provided in Fig. 1 . Each subject participated in one experiment, in which 400 ml water with (PRO) or without (PLA) 40 g intrinsically L-[1-
13 C]phenylalanine-labeled casein protein was administered via a nasogastric tube during overnight sleep from 0200 to 0205. Before and after protein administration, plasma and muscle samples were collected. These experiments were designed to simultaneously assess dietary protein digestion and absorption kinetics, splanchnic amino acid extraction, and mixed-muscle protein fractional synthetic rate (FSR) in vivo in humans during overnight sleep.
Protocol. At 1800, participants reported to the hospital ward where a nasogastric stomach feeding catheter (Bengmark; Flocare, Zoetermeer, the Netherlands) and two Teflon catheters were inserted. The first catheter was inserted in an antecubital vein, and the second catheter was inserted in an antecubital vein of the contralateral hand, which was placed in a hotbox to allow arterialized blood sampling (10a). After a background plasma sample was collected at 1855, the plasma phenylalanine pool was primed with a single intravenous dose of labeled phenylalanine and tyrosine (priming dose: 2.4 mol/kg MA), a standardized dinner was ingested at 1900. Participants rested in a supine position for 3 h. At 2300, the first muscle biopsy sample from the vastus lateralis muscle was taken. Subsequently, subjects went to sleep at 0000. During the night, at 0200, a bolus of 400 ml water with or without 40 g intrinsically labeled L- [1- 13 C]phenylalanine-labeled casein protein was administered via a nasogastric tube within 5 min without disturbing the subjects in their sleep. A second muscle biopsy was obtained from the vastus lateralis in the contralateral leg at 0700. Blood samples (8 ml) were taken from the arterialized hand vein at 1900, 2000, 2100, 2200, 2300, 0000, 0100, 0200, 0230, 0300, 0330, 0400, 0500, 0600 and 0700.
Blood samples were collected in EDTA-containing tubes and centrifuged at 1,000 g for 10 min at 4°C. Aliquots of plasma were frozen in liquid nitrogen and stored at Ϫ80°C. Muscle biopsies were obtained from the middle region of the vastus lateralis, 15 cm above the patella and ϳ4 cm below entry through the fascia, using the percutaneous needle biopsy technique (4). Muscle samples were dissected carefully and freed from any visible nonmuscle material. The muscle samples were immediately frozen in liquid nitrogen and stored at Ϫ80°C until further analysis.
Protein administration and tracer infusion. Intrinsically L-[1-13 C]phenylalanine-labeled casein protein was obtained by infusing a Holstein cow with large quantities of L-[1-
13 C]phenylalanine, collecting milk, and purifying the casein fraction as described previously (44) . The L-[1-
13 C]phenylalanine enrichment in the casein fraction averaged 37. 2 H2]tyrosine were purchased from Cambridge Isotopes and dissolved in 0.9% saline before infusion. Continuous intravenous infusions were performed using a calibrated IVAC 598 pump (San Diego, CA). Tracers were prepared by the pharmacy of the Maastricht University Medical Center.
Plasma analysis. Plasma glucose (Uni Kit III, 07367204; Roche, Basel, Switzerland) concentrations were analyzed with the COBAS-FARA semiautomatic analyzer (Roche). Insulin was analyzed by radioimmunoassay (Insulin RIA kit; LINCO Research, St. Charles, MO). Plasma (100 l) for amino acid analyses was deproteinized on ice with 4 mg/l of 24% (wt/vol) 5-sulfosalicylic acid and mixed, and the clear supernatant was collected after centrifugation. Plasma amino acid concentrations were analyzed by an automated RP-HPLC-based amino acid analyzer using an automated precolumn derivatization procedure and a ternary solvent system (43) . For plasma L-[1-
and L-[ring-
2 H2]tyrosine enrichment measurements, plasma phenylalanine and tyrosine were derivatized to their t-butyldimethylsilyl (TBDMS) derivatives, and their 13 C and/or 2 H enrichments were determined by electron ionization gas chromatographymass spectrometry (GC-MS; Agilent 6890N GC/5973N MSD) using selected ion monitoring of masses 336, 337, and 341 for labeled and L-[1-
C]-and L-[ring-
2 H5]phenylalanine, respectively. Masses 466, 467, 468, and 470 were assessed for labeled and unlabeled (1-13 C, ring-2 H2, and ring-2 H4) tyrosine (48) . We applied standard regression curves in all isotopic enrichment analyses to assess linearity of the mass spectrometer and to control for the loss of tracer. Enrichments (MPE) were calculated according to Biolo et al. (5) 2 H5]phenylalanine enrichment in the free amino acid pool and mixed-muscle protein, 55 mg of wet muscle was freeze-dried. Collagen, blood, and other nonmuscle fiber materials were removed from the muscle fibers under a light microscope. The isolated muscle fiber mass (2-3 mg) was weighed, and 35 vol (7ϫ wet wt of isolated muscle fibers ϫ wet-to-dry ratio 5:1) of ice-cold 2% perchloric acid (PCA) were added. The tissue was then homogenized and centrifuged. The supernatant was collected and processed in the same manner as the plasma samples, such that intracellular free L-[1-
13 C]phenylalanine and L-[ring-
2 H5]phenylalanine enrichments could be measured using their TBDMS derivatives on a GC-MS. The protein pellet was washed for three additional 1.5-ml washes of 2% PCA, dried, and hydrolyzed in 6 M HCl at 120°C for 15-18 h. The hydrolyzed protein fraction was dried under a nitrogen stream while heated to 120°C, then 50% acetic acid solution was added, and the hydrolyzed protein was passed over a Dowex exchange resin (AG 50W-X8, 100 -200 mesh hydrogen form; Bio-Rad, Hercules, CA) using 2 M NH4OH. The eluate was divided over two vials for separate measurement of both (18) . Thereafter, the ratios labeled/unlabeled derivatives were determined by GC-IRMS (MAT 252; Finnigan, Bremen, Germany) and GC-MS, respectively. Standard regression curves were applied to assess linearity of the mass spectrometer and to control for loss of tracer.
Calculations.
2 H5]phenylalanine, and arterialized blood sampling were used to assess whole body amino acid kinetics in non-steady-state conditions. Total, exogenous, and endogenous rate of appearance (Ra) and splanchnic extraction (i.e., fraction of dietary amino acid taken up by all other organs except from muscle tissue and plasma volume, Sp) for phenylalanine were calculated using modified Steele's equations (10, 13) . These parameters were calculated as follows:
where F is the intravenous tracer infusion rate (mol·kg Ϫ1 ·min Ϫ1 ) and pV (0.125) is the distribution volume for phenylalanine (10) . C(t) is the mean plasma phenylalanine concentration between two time points. ⌬E iv/⌬t represents the time-dependent variations of plasma phenylalanine enrichment derived from the intravenous tracer, and E iv(t) is the mean plasma phenylalanine enrichment from the intravenous tracer between two consecutive time points. ExoRa represents the plasma entry rate of dietary phenylalanine, Epo(t) is the mean plasma phenylalanine enrichment for the oral tracer, ⌬Epo/⌬t represents the time-dependent variations of plasma phenylalanine enrichment derived from the oral tracer, and Eprot is the L-[1-
13 C]phenylalanine enrichment in the dietary protein. Pheplasma calculates the percentage administered phenylalanine that becomes available in the plasma and is defined by Pheprot and AUCExoRa. PheProt is the amount of dietary phenylalanine ingested and AUCExoRa represents the area under the curve (AUC) of Exo Phe Ra, which corresponds to the amount of dietary phenylalanine that appeared in the blood over a 5-h period following administration by a nasogastric tube.
The total rate of disappearance of phenylalanine equals the rate of phenylalanine hydroxylation (first step in phenylalanine oxidation) and utilization for protein synthesis. This parameter is calculated as follows:
Because whole body R d comprise the rate of phenylalanine disappearance from the free amino acid pool in the blood due to protein synthesis (S) and oxidation, whole body protein synthesis can be calculated as R d minus oxidation. Whole body phenylalanine oxidation can be determined from the conversion (hydroxylation) of 
The fractional rate of mixed-muscle protein synthesis (FSR) was calculated by dividing the increment in enrichment in the product, i.e., protein-bound Statistics. All data are displayed as arithmetic means Ϯ SE (ϭ SD/ˆno. of subjects). Time-dependant variables like plasma amino acid concentrations, plasma enrichments, and whole body protein kinetics were analyzed by two-factor repeated-measures ANOVA and by calculating the AUC in both groups. Group-dependent variables such as AUC and FSR were analyzed by Student's t-test. Two-factor repeated-measures ANOVA was conducted with group as the between-subjects factor and time as the within-subjects factor. To differentiate the protein effect and to control group homogeneity before the intervention, two-factor repeated-measures ANOVA was carried out separately for the period from t ϭ Ϫ6 h to t ϭ 0 h and for the period after the protein administration between t ϭ 0 h and t ϭ 5 h. Statistical significance was set at P Ͻ 0.05. All calculations were performed using SPSS 15.0 (SPSS, Chicago, IL).
RESULTS
Plasma analysis. Plasma glucose and insulin concentrations increased rapidly after dinner and normalized to baseline levels before the first biopsy that was obtained at 2300. Plasma glucose concentrations averaged 5.2 Ϯ 0.0 and 5.5 Ϯ 0.1 mmol/l between 2300 and 0700 in the PLA and PRO experiment, respectively. Casein administration at 0200 did not modulate circulating plasma glucose concentrations. Plasma insulin concentrations between 2300 and 0700 averaged 10.7 Ϯ 0.3 and 19.1 Ϯ 2.1 mU/l in the PLA and PRO experiment, respectively (P Ͻ 0.05). Provision of intrinsically labeled casein resulted in a small but significant increase in circulating plasma insulin concentrations. Plasma insulin levels peaked 60 min after protein administration at 33.8 Ϯ 4.9 mU/l in the PRO experiment compared with 11.6 Ϯ 2.1 mU/l in the PLA experiment (P Ͻ 0.05). Thereafter, plasma insulin levels returned to values that were no longer different between experiments (data not shown).
Plasma phenylalanine, leucine, and essential amino acid concentrations over time are shown in Fig. 2 . No differences in basal plasma amino acid concentrations were observed between experimental groups. After administration of intrinsically labeled casein, plasma amino acid concentrations increased rapidly and remained significantly elevated for the remaining 5 h. Plasma amino acid concentrations were significantly higher in the PRO compared with the PLA experiment. Peak plasma phenylalanine (154 Ϯ 14 mol/l) and leucine (449 Ϯ 31 mol/l) concentrations were reached within 30 min after protein administration.
Continuous 13 C]phenylalanine-labeled casein was administered via a nasogastric tube at 0200 in the PRO experiment. Plasma tracer enrichments from infused and ingested amino acid tracers are shown in Fig. 3, A- (Fig. 3, A and B) . Plasma L-[1-
13 C]phenylalanine enrichments subsequently declined to 8.30 Ϯ 0.27 MPE 5 h after administration of the protein drink. No [1- 13 C]phenylalanine-labeled protein was provided in the PLA experiment, and, as such, enrichments levels were nil. Plasma L-[ring-2 H 5 ]phenylalanine and L-[ring-2 H 2 ]tyrosine enrichments declined following protein administration in the PRO experiment and remained well below the levels observed in the PLA experiment throughout the remainder of the night (Fig. 3, C  and D) .
Plasma amino acids kinetics. Whole body plasma amino acid kinetics are presented in Fig. 4 , A-E. Immediately after administration of the intrinsically labeled casein, exogenous [1- 13 C]phenylalanine entered the circulation. Exogenous phenylalanine appearance rates reached peak values at (0.43 Ϯ 0.03 mol·kg Ϫ1 ·min Ϫ1 ) within 60 min after protein administration (Fig. 4A) . In response, endogenous plasma phenylalanine appearance rates declined in the PRO experiment and remained well below levels observed in the PLA experiment. Whole body plasma phenylalanine disappearance rate followed the rate of appearance and showed significant postprandial phenylalanine disposal in the PRO experiment (Fig. 4C) (Fig. 4D) .
Calculated whole body protein synthesis and oxidation rates were significantly higher in the PRO vs. the PLA experiment. In agreement, net protein balance following protein adminis- 13 C]phenylalanine enrichment as precursor, mixed-muscle protein FSR from the ingested protein averaged 0.058 Ϯ 0.006%/h (Fig. 6B) .
Satiety after intervention. In the PRO experiment, subjects were provided with 40 g casein at night, representing 62.0 Ϯ 2.0% of their habitual daily protein intake. The following morning, hunger ratings were assessed by using the Visual Analog Scale with scores of 47 Ϯ 9 vs. 24 Ϯ 4% (P Ͻ 0.05) in the PLA and PRO experiments, respectively (36) . Energy intake (2.5 Ϯ 0.5 and 2.1 Ϯ 0.4 MJ; P ϭ 0.48) and total protein intake (20.9 Ϯ 4.9 and 18.2 Ϯ 3.3; P ϭ 0.65) with breakfast did not differ between the PLA and PRO experiments, respectively.
DISCUSSION
In the present study, we show that dietary protein administration by nasogastric tube feeding during overnight sleep is accompanied by normal dietary protein digestion and absorption kinetics in healthy, elderly men. Protein provision during sleep increases plasma amino acid availability and stimulates skeletal muscle protein synthesis, improving overnight whole body protein balance.
The loss of muscle mass with aging has been associated with a blunted skeletal muscle protein synthetic response to food intake (11, 21) . Consequently, many research groups have been trying to define effective dietary strategies to augment the postprandial muscle protein synthetic response to meal ingestion in the elderly (26, 27, 33, 45) . In contrast, we speculated on the potential to stimulate overnight muscle protein synthesis by providing dietary protein during sleep. The provision of protein during overnight sleep might enlarge the window of opportunity to improve 24-h protein balance. However, it is generally assumed that food digestion and absorption is not efficient during overnight sleep. It has been reported that human intestinal motility follows a circadian rhythm with reduced nocturnal activity (16, 23, 29) . Therefore, the first question that needs to be addressed is whether dietary protein administration during sleep is followed by normal protein digestion and absorption kinetics. Subsequently, it needs to be established whether this will effectively increase plasma amino acid availability, which is required to stimulate muscle protein synthesis (7, 12) . To address these questions, we administered 40 g intrinsically L-[1-
13 C]phenylalanine-labeled protein via a nasogastric tube in elderly subjects during their sleep (Fig. 1) . We specifically produced intrinsically L-[1-
13 C]phenylalaninelabeled milk protein by infusing large amounts of L-[1-13 C]phenylalanine in lactating Holstein cows (44) . The use of dietary protein with labeled amino acids incorporated within the protein allows accurate in vivo assessment of dietary protein digestion and absorption kinetics and the subsequent metabolic fate of the ingested amino acids in humans.
Directly after intragastric protein administration, plasma amino acid concentrations rapidly increased and remained elevated throughout the remainder of the night (Fig. 2) . Peak essential amino acid concentrations were observed within 30 min after protein administration (Fig. 2C) . The latter was entirely attributed to the digestion and absorption of the administered protein, since plasma L-[1-
13 C]phenylalanine enrichments increased immediately after protein administration, reaching peak values within 60 min (Fig. 3) . In accordance, calculated exogenous phenylalanine appearance rates rapidly increased following protein administration, showing that dietary protein provision during sleep is followed by normal dietary protein digestion and absorption (Fig. 4) . The latter does not seem to be different from digestion and absorption kinetics when protein is ingested during daytime. The amount of dietary protein-derived phenylalanine that became available in the circulation during the 5-h postprandial period averaged 58 Ϯ 4%. The latter is in line with previous work reporting similar findings after ingesting 20 -35 g casein or whey protein in the morning following an overnight fast (10, 28, 35) . In fact, when comparing the increase in exogenous amino acid appearance rates following casein ingestion reported in Koopman et al. (28) with the present findings, it might even be speculated that casein digestion and absorption was even more rapid when provided during overnight sleep. The present results demonstrate that the gastrointestinal tract is fully functional during overnight sleep when food is made available, allowing proper dietary protein digestion and absorption in healthy, elderly men.
We combined the use of specifically produced, high-level intrinsically L-[1-
13 C]phenylalanine-labeled dietary protein with continuous intravenous L-[ring-2 H 5 ]phenylalanine infusion to allow accurate assessment of exogenous protein digestion and absorption kinetics but also to study its subsequent impact on whole body and muscle protein metabolism. Whole body muscle protein synthesis rates increased rapidly following protein administration, resulting in much higher whole body protein synthesis rates in the PLA vs. PRO experiment (Fig. 5) . In agreement, overnight whole body protein balance was more positive in the PRO compared with the PLA experiment. The latter shows that dietary protein provided during sleep is absorbed and retained, thereby allowing whole body protein accretion. However, it should be noted that changes in whole body protein kinetics do not necessarily represent changes on a muscle tissue level (30) .
Therefore, we also determined mixed-muscle protein fractional synthesis rates by measuring both the incorporation of when protein was provided during sleep. These results show that protein administration during sleep strongly stimulates mixed-muscle protein synthesis (Fig. 6A) . These findings were obtained despite the fact that our subjects had consumed a standardized diet that provided ample dietary protein (ϳ70 g protein) throughout the day. The latter underlines the efficacy of nighttime protein provision to modulate muscle protein synthesis. The application of intrinsically L-[1-
13 C]phenylalanine-labeled casein, with an enrichment level of up to 40 MPE (44), allows us to also assess the incorporation of the absorbed L-[1-
13 C]phenylalanine into skeletal muscle protein. In the PRO experiment, muscle protein-bound L-[1-
13 C]phenylalanine had increased substantially, which translated into a fractional mixed-muscle protein synthesis rate of 0.058 Ϯ 0.006%/h (Fig. 6B) . The latter provides direct evidence that dietary protein administered during sleep is not only adequately digested and absorbed but is also effectively used for de novo muscle protein synthesis.
Evidence for proper nocturnal protein digestion and absorption as well as subsequent de novo muscle protein synthesis in vivo may be of clinical relevance. The concept of overnight protein provision can be translated to more practical dietary interventions. For example, specifically designed proteins or prebedtime protein meals might be applied to allow dietary protein provision throughout overnight sleep. In the present study, the large amounts of dietary protein (40 g) administered during sleep were well received and did not cause any gastrointestinal disturbances or nausea. In fact, none of the subjects woke up during or immediately after administration of the protein (or placebo) solution. It could be speculated that overnight protein provision might modulate food intake during the subsequent day(s). Although beyond the scope of the study, we assessed hunger levels before breakfast (41) . Lower hunger ratings were reported when protein was provided during sleep. However, the latter did not seem to affect energy and/or protein intake during subsequent breakfast. So far, the present study suggests that it is possible to expand the window for nutritional support by protein provision during the night. Consequently, future research should investigate whether nighttime protein provision could represent a feasible concept to attenuate muscle mass loss in various clinical conditions (24, 42) , such as (postsurgical) muscle wasting (17, 22, 38) and cachexia in postcancer (31, 49) , chronic obstructive pulmonary disease (39) , and cardiac disease (2, 15, 32) . The specific nutritional requirements and practical implications in such clinical subpopulations raise numerous interesting questions.
In conclusion, this study proves that protein administration during overnight sleep is followed by proper dietary protein digestion and absorption kinetics, thereby increasing plasma amino acid availability throughout the night. An increase in overnight plasma amino acid availability stimulates muscle protein synthesis during sleep and improves overnight whole body protein balance in elderly males. Nocturnal dietary protein administration may represent an effective nutritional intervention strategy to support muscle mass maintenance in both health and disease.
